AU2011350995B2 - Inactivated poliovaccine - Google Patents

Inactivated poliovaccine Download PDF

Info

Publication number
AU2011350995B2
AU2011350995B2 AU2011350995A AU2011350995A AU2011350995B2 AU 2011350995 B2 AU2011350995 B2 AU 2011350995B2 AU 2011350995 A AU2011350995 A AU 2011350995A AU 2011350995 A AU2011350995 A AU 2011350995A AU 2011350995 B2 AU2011350995 B2 AU 2011350995B2
Authority
AU
Australia
Prior art keywords
poliovirus
sabin
stem
coding region
inactivated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011350995A
Other languages
English (en)
Other versions
AU2011350995A8 (en
AU2011350995A1 (en
Inventor
Andrew Macadam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Health and Social Care
Original Assignee
UK Secretary of State for Health and Social Care
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Health and Social Care filed Critical UK Secretary of State for Health and Social Care
Publication of AU2011350995A1 publication Critical patent/AU2011350995A1/en
Publication of AU2011350995A8 publication Critical patent/AU2011350995A8/en
Application granted granted Critical
Publication of AU2011350995B2 publication Critical patent/AU2011350995B2/en
Assigned to Secretary of State for Health and Social Care reassignment Secretary of State for Health and Social Care Request for Assignment Assignors: THE SECRETARY OF STATE FOR HEALTH
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C12N2770/32662—Methods of inactivation or attenuation by genetic engineering
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2011350995A 2010-12-29 2011-12-29 Inactivated poliovaccine Active AU2011350995B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1022077.0 2010-12-29
GBGB1022077.0A GB201022077D0 (en) 2010-12-29 2010-12-29 Inactivated poliovaccine
PCT/GB2011/001779 WO2012090000A1 (en) 2010-12-29 2011-12-29 Inactivated poliovaccine

Publications (3)

Publication Number Publication Date
AU2011350995A1 AU2011350995A1 (en) 2013-07-04
AU2011350995A8 AU2011350995A8 (en) 2013-07-18
AU2011350995B2 true AU2011350995B2 (en) 2016-11-24

Family

ID=43599090

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011350995A Active AU2011350995B2 (en) 2010-12-29 2011-12-29 Inactivated poliovaccine

Country Status (13)

Country Link
US (1) US9402892B2 (enExample)
EP (1) EP2658571B1 (enExample)
JP (1) JP5955860B2 (enExample)
CN (1) CN103391788B (enExample)
AU (1) AU2011350995B2 (enExample)
BR (1) BR112013017014B1 (enExample)
CA (1) CA2821859C (enExample)
DK (1) DK2658571T3 (enExample)
ES (1) ES2574178T3 (enExample)
GB (1) GB201022077D0 (enExample)
RU (1) RU2599453C2 (enExample)
WO (1) WO2012090000A1 (enExample)
ZA (1) ZA201304415B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615933D0 (en) 2006-08-10 2006-09-20 Nat Inst Biological Standards & Control Attenuated polioviruses
JP6591461B2 (ja) * 2014-06-17 2019-10-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 低温適応性ウイルス弱毒化（ｃａｖａ）および新規の弱毒化ポリオウイルス株
GB201700825D0 (en) * 2017-01-17 2017-03-01 Sec Dep For Health Poliovaccine
CN112312925B (zh) * 2018-03-30 2024-09-17 生物模仿公司 辐照灭活的脊髓灰质炎病毒、包含其的组合物及制备方法
WO2020075197A1 (en) * 2018-10-10 2020-04-16 Biological E Limited Inactivated poliomyelitis vaccine composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017870A1 (en) * 2006-08-10 2008-02-14 National Biological Standards Board Attenuated polio viruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8901094D0 (en) 1989-01-18 1989-03-15 Almond Jeffrey W Attenuated viruses
RU2215035C2 (ru) * 1991-12-06 2003-10-27 Уайтхэд институт фор биомедикл рисерч Рекомбинантный полиовирусный вектор (варианты), способ его получения (варианты), способ индукции иммунного ответа у индивидуума (варианты), способ получения белка (варианты), вакцинная композиция для терапии или профилактики инфекционных заболеваний (варианты)
GB9705669D0 (en) 1997-03-19 1997-05-07 British Tech Group Attenuated polioviruses
GB9817082D0 (en) * 1998-08-06 1998-10-07 Btg Int Ltd Attenuated poliovirus vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017870A1 (en) * 2006-08-10 2008-02-14 National Biological Standards Board Attenuated polio viruses

Also Published As

Publication number Publication date
RU2013135290A (ru) 2015-02-10
EP2658571A1 (en) 2013-11-06
US20130344108A1 (en) 2013-12-26
RU2599453C2 (ru) 2016-10-10
BR112013017014B1 (pt) 2020-12-15
CA2821859C (en) 2020-07-07
WO2012090000A1 (en) 2012-07-05
BR112013017014A2 (pt) 2016-10-25
JP2014502508A (ja) 2014-02-03
JP5955860B2 (ja) 2016-07-20
CN103391788B (zh) 2016-04-20
EP2658571B1 (en) 2016-03-02
AU2011350995A8 (en) 2013-07-18
CA2821859A1 (en) 2012-07-05
US9402892B2 (en) 2016-08-02
GB201022077D0 (en) 2011-02-02
ES2574178T3 (es) 2016-06-15
DK2658571T3 (en) 2016-05-17
CN103391788A (zh) 2013-11-13
ZA201304415B (en) 2014-03-26
AU2011350995A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
US5298416A (en) Attenuated polioviruses
US11938180B2 (en) Poliovaccine
US9402892B2 (en) Inactivated poliovaccine
CN106459929A (zh) 冷适应病毒减毒(cava)和新颖减毒脊髓灰质炎病毒株
US9408903B2 (en) Vaccination method employing genetically stable attenuated polioviruses comprising multiple mutations in domain V of the 5′ noncoding region
CA2045649C (en) Attenuated enteroviruses and rhinoviruses
US5639462A (en) Attenuated polyiviruses vaccine containing them and vaccination methods using them
EP0508783A1 (en) Attenuated poliovirus and vaccines thereof
WO1998041619A1 (en) Attenuated polioviruses

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 27 , NO 25 , PAGE(S) 3801 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME HEALTH PROTECTION AGENCY, APPLICATION NO. 2011350995, UNDER INID (71) CORRECT THE APPLICANT NAME TO THE SECRETARY OF STATE FOR HEALTH

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE

Free format text: FORMER OWNER(S): THE SECRETARY OF STATE FOR HEALTH